Older Women’s Views about Prescription Osteoporosis Medication
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Osteoporosis is a significant health problem, especially for older women. Prescription osteoporosis medication can reduce fractures, but many women do not accept treatment or discontinue treatment before benefits are achieved.
Objectives: To explore older women’s views about prescription osteoporosis medication use in depth and to identify specific beliefs and experiences that influence these views.
Methods: We conducted in-depth telephone interviews with women aged ≥65 years with clinically confirmed osteoporosis. Interviewees were asked about their beliefs and experiences related to osteoporosis and osteoporosis treatment. Interviews were recorded and transcribed; key themes were identified using qualitative analysis.
Results: Perceived need, medication effectiveness and medication safety were identified as critical influences on women’s views about prescription osteoporosis medication. These perceptions were in turn influenced by various beliefs, experiences and behaviours, including interactions with the physician, personal experience and behaviours, and vicarious experience.
Conclusions: Older women with osteoporosis need clear information about their condition, including the diagnosis, the implications of the diagnosis, treatment options, medication effectiveness and side effects. Physicians should check with their patients to confirm understanding and address concerns, as older women may not always voice their reservations and concerns.
- National Osteoporosis Foundation. Fast facts on osteoporosis [online]. Available from URL: http://www.nof.org/osteoporosis/diseasefacts.htm [Accessed 2010 Feb 04]
- Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009 Feb; 122(2 Suppl.): S3–13 CrossRef
- Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 Aug; 81(8): 1013–22 CrossRef
- Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004 Dec; 15(12): 1003–8 CrossRef
- Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006 Jun; 38(6): 922–8 CrossRef
- Penning-van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008 Apr; 19(4): 511–7 CrossRef
- Gallagher AM, Rietbrock S, Olson M, et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008 Oct; 23(10): 1569–75 CrossRef
- Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003 Dec; 14(12): 965–8 CrossRef
- Yood RA, Mazor KM, Andrade SE, et al. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008 Nov; 23(11): 1815–21 CrossRef
- Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005 Nov 14; 165(20): 2414–9 CrossRef
- Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24(1): 37–55 CrossRef
- Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003 Aug; 115(3): 209–16 CrossRef
- McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004 Jul; 48(3): 271–87 CrossRef
- Briesacher BA, Andrade SE, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Bone 2007 Nov; 41(5): 882–7 CrossRef
- Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 2008 Oct; 19(10): 1421–9 CrossRef
- Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005 Jan–Jun; Suppl. Web Exclusives: W5-152-W5-66
- McHorney CA, Schousboe JT, Cline RR, et al. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 2007 Dec; 23(12): 3137–52 CrossRef
- Johnson MJ. The medication adherence model: a guide for assessing medication taking. Res Theory Nurs Pract 2002 Fall; 16(3): 179–92 CrossRef
- Janz N, Champion V, Strecher V. The health belief model. In: Glanz K, Rimer B, Lewis F, editors. Health behavior and health education. 3rd ed. San Francisco (CA): Jossey-Bass, 2002: 45–66
- Older Women’s Views about Prescription Osteoporosis Medication
Drugs & Aging
Volume 27, Issue 12 , pp 999-1008
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Meyers Primary Care Institute, Worcester, Massachusetts, USA
- 2. University of Massachusetts Medical School, Worcester, Massachusetts, USA
- 3. Fallon Clinic, Worcester, Massachusetts, USA
- 4. Fallon Community Health Plan, Worcester, Massachusetts, USA